TapewireFind a company

person · Reporting owner

Anders Jack

Disclosed activity across 1 company

Tapewire entity
35163
SEC CIK
0001800668

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Revolution Medicines, Inc.RVMD · Entity 606Chief Financial OfficerSeptember 16, 2026September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect123,208 Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-16 · Sale · Disposed 61 · Balance 123,208

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

Common StockSEC Table I · non-derivativeDirect119,216 Reported balance After 2026-09-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-09-16 · Sale · Disposed 3,992 · Balance 119,216

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: Includes 43,650 restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: Includes 43,650 restricted stock units.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 23, 2023 Filed Oct 23, 2023 22:01 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionStock Option (Right to Buy) · Derivative 5,137 $0.00 Strike: $4.09 $0.00
Disclosure

SEC source: 0001610717-23-000313 · form4.xml · derivative · entry 4

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,137 shares

Expires 2029-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 23, 2023 Filed Oct 23, 2023 22:01 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionStock Option (Right to Buy) · Derivative 19,387 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001610717-23-000313 · form4.xml · derivative · entry 3

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,814

Underlying: Common Stock · 19,387 shares

Expires 2028-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 23, 2023 Filed Oct 23, 2023 22:01 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionCommon Stock 5,137 $4.09 $21,010.33
Disclosure

SEC source: 0001610717-23-000313 · form4.xml · nonDerivative · entry 2

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 40,800 restricted stock units.

Read SEC document
October 23, 2023 Filed Oct 23, 2023 22:01 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionCommon Stock 19,387 $2.68 $51,957.16
Disclosure

SEC source: 0001610717-23-000313 · form4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 40,800 restricted stock units.

Read SEC document
September 18, 2023 Filed Sep 20, 2023 20:11 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 1,427 $31.31 $44,680.23
Disclosure

SEC source: 0001610717-23-000292 · form4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,667

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · price: This transaction was executed in multiple trades in prices ranging from $31.101 to $31.3108, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 40,800 restricted stock units.

Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:02 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001610717-23-000259 · form4.xml · derivative · entry 3

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,201

Underlying: Common Stock · 20,000 shares

Expires 2028-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.

Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:02 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 20,000 $35.05 $701,092.00
Disclosure

SEC source: 0001610717-23-000259 · form4.xml · nonDerivative · entry 2

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,094

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.

F3 · price: This transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 44,276 restricted stock units.

Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:02 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionCommon Stock 20,000 $2.68 $53,600.00
Disclosure

SEC source: 0001610717-23-000259 · form4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.

F2 · balance_after: Includes 44,276 restricted stock units.

Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:25 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 1,249 $24.89 $31,088.86
Disclosure

SEC source: 0001610717-23-000193 · form4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,094

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · balance_after: Includes 1,110 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023.

F3 · balance_after: Includes 44,276 RSUs.

Read SEC document
March 17, 2023 Filed Mar 22, 2023 00:33 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 665 $21.78 $14,483.70
Disclosure

SEC source: 0000899243-23-009376 · doc4.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,233

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · price: This transaction was executed in multiple trades in prices ranging from $21.4075 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 47,750 RSUs.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:17 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantStock Option (Right to Buy) · Derivative 93,100 $0.00 Strike: $26.50 $0.00
Disclosure

SEC source: 0001567619-23-004356 · doc1.xml · derivative · entry 2

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,100

Underlying: Common Stock · 93,100 shares

Expires 2033-02-28

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:17 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantCommon Stock 26,600 $0.00 $0.00
Disclosure

SEC source: 0001567619-23-004356 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,898

F1 · balance_after: Includes 49,563 restricted stock units.

Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:08 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 658 $22.94 $15,094.85
Disclosure

SEC source: 0001567619-22-021930 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,298

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · price: This transaction was executed in multiple trades in prices ranging from $22.4716 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 22,964 RSUs.

Read SEC document
September 19, 2022 Filed Sep 21, 2022 20:17 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 449 $19.04 $8,550.13
Disclosure

SEC source: 0001567619-22-017689 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,956

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · price: This transaction was executed in multiple trades in prices ranging from $18.98 to $19.0337, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 24,776 RSUs.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:18 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantStock Option (Right to Buy) · Derivative 35,000 $0.00 Strike: $21.61 $0.00
Disclosure

SEC source: 0001567619-22-016989 · doc1.xml · derivative · entry 2

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-08-31

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
September 01, 2022 Filed Sep 2, 2022 20:18 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001567619-22-016989 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,405

F1 · balance_after: Includes 25,964 restricted stock units.

Read SEC document
June 17, 2022 Filed Jun 22, 2022 21:01 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 406 $17.75 $7,206.30
Disclosure

SEC source: 0001567619-22-013250 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,405

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · balance_after: Includes 936 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022.

F3 · balance_after: Includes 15,964 RSUs.

Read SEC document
March 17, 2022 Filed Mar 22, 2022 00:01 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 159 $18.62 $2,959.98
Disclosure

SEC source: 0001567619-22-007323 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,875

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · price: This transaction was executed in multiple trades in prices ranging from $18.32 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 17,151 RSUs.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:26 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantStock Option (Right to Buy) · Derivative 40,600 $0.00 Strike: $18.56 $0.00
Disclosure

SEC source: 0001567619-22-006234 · doc1.xml · derivative · entry 2

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,600

Underlying: Common Stock · 40,600 shares

Expires 2032-02-29

F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:26 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantCommon Stock 11,600 $0.00 $0.00
Disclosure

SEC source: 0001567619-22-006234 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,034

F1 · balance_after: Includes 17,613 Restricted Stock Units.

Read SEC document
December 17, 2021 Filed Dec 21, 2021 21:34 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 170 $24.41 $4,149.70
Disclosure

SEC source: 0001567619-21-022406 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,434

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · balance_after: Includes 412 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2021.

F3 · balance_after: Includes 6,013 RSUs.

Read SEC document
September 17, 2021 Filed Sep 21, 2021 23:48 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 166 $30.02 $4,983.32
Disclosure

SEC source: 0001567619-21-017417 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,192

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · balance_after: Includes 6,475 RSUs.

Read SEC document
June 17, 2021 Filed Jun 22, 2021 21:16 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 160 $34.12 $5,459.86
Disclosure

SEC source: 0001567619-21-012487 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,358

F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F2 · price: This transaction was executed in multiple trades in prices ranging from $33.66 to $34.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 614 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021.

F4 · balance_after: Includes 6,938 RSUs.

Read SEC document
March 04, 2021 Filed Mar 9, 2021 00:42 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantStock Option (Right to Buy) · Derivative 25,900 $0.00 Strike: $42.45 $0.00
Disclosure

SEC source: 0001567619-21-005847 · doc1.xml · derivative · entry 2

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,900

Underlying: Common Stock · 25,900 shares

Expires 2031-03-03

F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
March 04, 2021 Filed Mar 9, 2021 00:42 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantCommon Stock 7,400 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-005847 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,904

F1 · balance_after: Includes 7,400 Restricted Stock Units.

F2 · balance_after: Includes 504 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 23:14 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001567619-20-017887 · doc1.xml · derivative · entry 3

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,201

Underlying: Common Stock · 10,000 shares

Expires 2028-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vest on the first anniversary measured from August 16, 2018 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 23:14 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 10,000 $44.00 $440,000.00
Disclosure

SEC source: 0001567619-20-017887 · doc1.xml · nonDerivative · entry 2

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 23:14 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionCommon Stock 10,000 $2.68 $26,800.00
Disclosure

SEC source: 0001567619-20-017887 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 21:07 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001567619-20-017693 · doc1.xml · derivative · entry 3

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,201

Underlying: Common Stock · 10,000 shares

Expires 2028-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · derivative.exercise_date: This option is early exercisable. Twenty-five percent of the total shares subject to the option vest on the first anniversary measured from August 16, 2018 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 21:07 UTC Revolution Medicines, Inc. RVMD · Entity 606 SaleCommon Stock 10,000 $40.00 $400,000.00
Disclosure

SEC source: 0001567619-20-017693 · doc1.xml · nonDerivative · entry 2

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
October 06, 2020 Filed Oct 8, 2020 21:07 UTC Revolution Medicines, Inc. RVMD · Entity 606 Exercise / conversionCommon Stock 10,000 $2.68 $26,800.00
Disclosure

SEC source: 0001567619-20-017693 · doc1.xml · nonDerivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
February 12, 2020 Filed Feb 14, 2020 21:21 UTC Revolution Medicines, Inc. RVMD · Entity 606 GrantStock Option (Right to Buy) · Derivative 17,467 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0001567619-20-004010 · doc1.xml · derivative · entry 1

Anders Jack · CIK 0001800668 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,467

Underlying: Common Stock · 17,467 shares

Expires 2030-02-11

F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/48 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.